GH Research
GHRS | NASDAQ
$18.75
-$0.35 (-1.83%)
At close: Nov 16, 2026, 4:00 PM ET
$18.75
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
GH Research Company Profile
Company profile explainedCompany Profile
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Key Executives
| Name | Position |
|---|---|
| Velichka Valcheva | Chief Executive Officer |
| Aaron Cameron | Chief Operating Officer |
| Florian Schonharting | Co-Founder & Non-Executive Chairman of the Board |
| Julie Ryan | Vice President of Finance |
| Magnus Halle | Co-Founder & MD of Ireland |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | 6-K | Filing |
| Sep 11, 2026 | 6-K | Filing |
| Sep 09, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 06, 2026 | 6-K | Filing |
| Jun 26, 2026 | 6-K | Filing |
GH Research
| Country | Ireland |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Velichka Valcheva |
Contact Details
Joshua Dawson House Dublin,
DU D02 RY95 Ireland
Stock Details
| Ticker Symbol | GHRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855129 |
| CUSIP Number | G3855L106 |
| ISIN Number | IE000GID8VI0 |
| SIC Code | 2834 |
Recent News
- 3 days ago / globenewswire.comGH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
- 3 days ago / globenewswire.comGH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
- 25 days ago / seekingalpha.comGH Research Remains Undervalued Ahead Of Pivotal Phase III Program
- 2 months ago / seekingalpha.comGH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
- 3 months ago / globenewswire.comGH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
- 4 months ago / proactiveinvestors.comPsychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
- 6 months ago / globenewswire.comGH Research Announces Publication of Phase 2a Postpartum Depression Results
- 6 months ago / seekingalpha.comGH Research: Rapid Onset And Short Action Change The Treatment Paradigm
- 6 months ago / benzinga.comThese Analysts Revise Their Forecasts On GH Research After Q1 Results
- 6 months ago / globenewswire.comGH Research Reports First Quarter 2026 Financial Results and Provides Business Update
Add to Watchlist
Select watchlists to add or remove GHRS